Cancer immunomics: from serological proteome analysis to multiple affinity protein profiling.
Cancer remains one of the leading causes of death worldwide. Thus, to identify any useful biomarkers is still a need. We performed "cancer immunomics" to identify autoantibody signatures produced in response to the presence of either breast or colorectal cancer. SERological proteome analysis (SERPA) was performed by two-dimensional (2-D) electrophoresis separation, immunoblotting, image analysis, and mass spectrometry. Alternatively, to identify the antigens recognized by the autoantibodies of cancer patients, we developed an approach combining 2-D immunoaffinity chromatography, enzymatic digestion of the isolated antigens, nano flow separation of the resulting peptides, and identification: MAPPing (multiple affinity protein profiling). By these approaches we identified both proteins recognized by autoantibodies independently of a cancer status, and a limited number of proteins reacting preferentially with cancer sera.
Hardouin
Julie
J
Protein Biochemistry and Proteomics Laboratory, CNRS UMR 7033 (BioMoCeti), UFR SMBH Leonard de Vinci, University Paris13, 74, rue Marcel Cachin, 93017 Bobigny cedex, France.
Lasserre
Jean-Paul
JP
Sylvius
Loïk
L
Joubert-Caron
Raymonde
R
Caron
Michel
M
D000941:Antigens / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology; D014408:Biomarkers, Tumor; D006801:Humans; D009369:Neoplasms / Q000097:blood* / Q000276:immunology*; D020543:Proteome / Q000276:immunology* / Q000378:metabolism*; D040901:Proteomics